<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/'><id>tag:blogger.com,1999:blog-2983847494764530248.post7386070118815973810..comments</id><updated>2010-10-11T22:39:07.465+09:00</updated><category term='◆Cefcapene Pivoxil'/><category term='★★★'/><category term='Need for data'/><category term='◆Vardenafil'/><category term='*Case2002'/><category term='Injunction'/><category term='*Case2009'/><category term='◆Tamsulosin'/><category term='*Case1991-2000'/><category term='◆Ebastine'/><category term='◆Pravastatin'/><category term='Selection invention'/><category term='Amendment/New matter'/><category term='◆Sarpogrelate'/><category term='◆Alendronate'/><category term='◆Cefdinir'/><category term='*Case2010'/><category term='*Case1971-1980'/><category term='Product-by-process'/><category term='Patent term extension'/><category term='Formality'/><category term='◆Valsartan'/><category term='*Case2006'/><category term='Priority right'/><category term='・Composition/Formulation'/><category term='◆Tafluprost'/><category term='◆Buprenorphine'/><category term='　・Purification/Impurity'/><category term='Post-published prior art'/><category term='◆Acarbose'/><category term='◆Buserelin'/><category term='*Case2011'/><category term='*Topics'/><category term='*Pharma/IP news'/><category term='Inventive step/Obviousness'/><category term='・Package/Container'/><category term='・Dosage regimen'/><category term='◆Sevoflurane'/><category term='◆Ciclosporin'/><category term='◆Tadalafil'/><category term='*Case2003'/><category term='★'/><category term='・Indication'/><category term='Infringement'/><category term='◆Donepezil'/><category term='◆Beclometasone'/><category term='◆Leuprorelin'/><category term='Utility/Description requirement'/><category term='Inventorship/Remuneration'/><category term='*Case2007'/><category term='*Case2012'/><category term='・Polymorph'/><category term='Design'/><category term='*Case2004'/><category term='◆Kremezin'/><category term='*Case2001'/><category term='◆Pioglitazone'/><category term='・・・Thanks for your comments'/><category term='・Screening assay/tool'/><category term='Trademark/Unfair competition'/><category term='◆Atorvastatin'/><category term='◆Rosiglitazone'/><category term='◆Etanercept'/><category term='・Optical isomer'/><category term='◆Paclitaxel'/><category term='・Process/Manufacture'/><category term='◆Morphine'/><category term='・Salt/Solvate'/><category term='*Case2008'/><category term='・Combination therapy'/><category term='*Case2005'/><category term='◆Rosuvastatin'/><category term='・Purification/Impurity'/><category term='◆Levofloxacin'/><category term='◆Oxiglutatione'/><category term='Novelty'/><category term='◆Lansoprazole'/><category term='◆Lamivudine'/><category term='◆Rabeprazole'/><category term='◆Sildenafil'/><category term='Advantageous effects'/><category term='★★'/><category term='・Compound'/><title type='text'>Comments on 「医薬系 "特許的" 判例」 ブログ: アリセプト特許権存続期間延長登録 無効審決取消訴訟</title><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://www.tokkyoteki.com/feeds/7386070118815973810/comments/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/2983847494764530248/7386070118815973810/comments/default'/><link rel='alternate' type='text/html' href='http://www.tokkyoteki.com/2010/10/blog-post_11.html'/><author><name>Fubuki</name><uri>http://www.blogger.com/profile/17180300759644628572</uri><email>noreply@blogger.com</email><gd:image xmlns:gd='http://schemas.google.com/g/2005' rel='http://schemas.google.com/g/2005#thumbnail' width='27' height='32' src='http://1.bp.blogspot.com/_-QTWVbT1hWM/TUl3ryAu32I/AAAAAAAAAw4/_8NIMsvBny4/s220/Fubuki.JPG'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>0</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage></feed>
